PURPOSE: The purpose of this study was to examine the therapeutic effect of magnetic nanoparticle hyperthermia (mNPH) combined with systemic cisplatin chemotherapy in a murine mammary adenocarcinoma model (MTGB). MATERIALS AND METHODS: An alternating magnetic field (35.8 kA/m at 165 kHz) was used to activate 110 nm hydroxyethyl starch-coated magnetic nanoparticles (mNP) to a thermal dose of 60 min at 43 °C. Intratumoral mNP were delivered at 7.5 mg of Fe/cm(3) of tumour (four equal tumour quadrants). Intraperitoneal cisplatin at 5 mg/kg body weight was administered 1 h prior to mNPH. Tumour regrowth delay time was used to assess the treatment efficacy. RESULTS: mNP hyperthermia, combined with cisplatin, was 1.7 times more effective than mNP hyperthermia alone and 1.4 times more effective than cisplatin alone (p < 0.05). CONCLUSIONS: Our results demonstrate that mNP hyperthermia can result in a safe and significant therapeutic enhancement for cisplatin cancer therapy.
PURPOSE: The purpose of this study was to examine the therapeutic effect of magnetic nanoparticle hyperthermia (mNPH) combined with systemic cisplatin chemotherapy in a murine mammary adenocarcinoma model (MTGB). MATERIALS AND METHODS: An alternating magnetic field (35.8 kA/m at 165 kHz) was used to activate 110 nm hydroxyethyl starch-coated magnetic nanoparticles (mNP) to a thermal dose of 60 min at 43 °C. Intratumoral mNP were delivered at 7.5 mg of Fe/cm(3) of tumour (four equal tumour quadrants). Intraperitoneal cisplatin at 5 mg/kg body weight was administered 1 h prior to mNPH. Tumour regrowth delay time was used to assess the treatment efficacy. RESULTS:mNPhyperthermia, combined with cisplatin, was 1.7 times more effective than mNPhyperthermia alone and 1.4 times more effective than cisplatin alone (p < 0.05). CONCLUSIONS: Our results demonstrate that mNPhyperthermia can result in a safe and significant therapeutic enhancement for cisplatincancer therapy.
Authors: P J van de Vaart; N van der Vange; F A Zoetmulder; A R van Goethem; O van Tellingen; W W ten Bokkel Huinink; J H Beijnen; H Bartelink; A C Begg Journal: Eur J Cancer Date: 1998-01 Impact factor: 9.162
Authors: Robert V Stigliano; Fridon Shubitidze; James D Petryk; Levan Shoshiashvili; Alicia A Petryk; P Jack Hoopes Journal: Int J Hyperthermia Date: 2016-07-20 Impact factor: 3.914
Authors: Ian Baker; Steve N Fiering; Karl E Griswold; P Jack Hoopes; Katerina Kekalo; Christian Ndong; Keith Paulsen; Alicea A Petryk; Brian Pogue; Fridon Shubitidze; John Weaver Journal: Nanomedicine (Lond) Date: 2015 Impact factor: 5.307
Authors: Anastasia K Hauser; Robert J Wydra; Nathanael A Stocke; Kimberly W Anderson; J Zach Hilt Journal: J Control Release Date: 2015-09-25 Impact factor: 9.776
Authors: Christian Ndong; Seiko Toraya-Brown; Katsiaryna Kekalo; Ian Baker; Tillman U Gerngross; Steven N Fiering; Karl E Griswold Journal: Int J Nanomedicine Date: 2015-04-01